<DOC>
	<DOCNO>NCT00170690</DOCNO>
	<brief_summary>Comparison patient compliance treosulfan oral vs. intravenous ( defined end therapy patient )</brief_summary>
	<brief_title>Preference Study With Elderly Patients Recurrent Ovarian Cancer</brief_title>
	<detailed_description>Approximately 60 % cancer diseases appear people age 65 year old . Ovarian cancer frequent cause death among gynaecological malignant tumour . Since high carcinoma incidence 60th 70th year woman come ovarian cancer increase life expectancy . At least 65 % patient FIGO stage III/IV exhibit relapse progress first-line therapy . In study age patient limit 65 year . It could show especially elder patient often receive inadequate operative cytostatic therapy result bad prognosis . Patients age 70 year elder treat treosulfan , give oral intravenous , shall compare regard patient compliance , toxicity especially hematological gastrointestinal toxicity grade 3-4 ( CTC NCI ) , overall survival , progression free survival , quality life .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>patient relapse ovarian cancer study therapy third regime measurable evaluable tumor lesion progression define CA125 &gt; = 100 U/ ml . Age &gt; = 70 year ECOG 02 write informed consent Pretreatment treosulfan patient without measurable evaluable tumor lesion CA125 &gt; = 100 U/ ml . adequate bone marrow function ( leukocyte &lt; = 2,9 x 109/l , platelet &lt; = 100 x 109/ l creatinin bilirubin within &gt; = 1,25 x fold reference laboratoryÂ´s normal range simultaneous radiotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>